MedPath

Rogaratinib

Generic Name
Rogaratinib
Drug Type
Small Molecule
Chemical Formula
C23H26N6O3S
CAS Number
1443530-05-9
Unique Ingredient Identifier
98BSN6N516

Overview

Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2020/10/22
Phase 2
Active, not recruiting
2019/10/14
Phase 2
Completed
2019/08/01
Phase 2
Withdrawn
2018/12/27
Phase 1
Completed
2018/12/03
Phase 2
Terminated
2018/05/08
Phase 1
Completed
2018/04/02
Phase 1
Completed
2018/03/22
Phase 1
Completed
2018/01/25
Phase 2
Completed
2015/10/30
Phase 1
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.